FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Opipari Anthony W.
(Last) (First) (Middle)
C/O ODYSSEY THERAPEUTICS, INC.
51 SLEEPER STREET, SUITE 800
(Street)
BOSTON MA 02210
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2026 		3. Issuer Name and Ticker or Trading Symbol
Odyssey Therapeutics, Inc. [ ODTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 10/06/2031 Common Stock 9,335 3.98 D  
Stock Option (Right to Buy)   (1) 12/16/2031 Common Stock 9,570 3.98 D  
Stock Option (Right to Buy)   (2) 12/09/2031 Common Stock 2,058 3.98 D  
Stock Option (Right to Buy)   (3) 03/06/2034 Common Stock 9,716 3.98 D  
Stock Option (Right to Buy)   (4) 09/09/2035 Common Stock 13,314 4.18 D  
Stock Option (Right to Buy)   (5) 09/09/2035 Common Stock 39,943 4.18 D  
Series A Convertible Preferred Stock   (6)   (6) Common Stock 1,907 (6) D  
Series B Convertible Preferred Stock   (7)   (7) Common Stock 1,194 (7) D  
Series C Convertible Preferred Stock   (8)   (8) Common Stock 2,058 (8) D  
Series D Convertible Preferred Stock   (9)   (9) Common Stock 1,806 (9) D  
Series D Warrants (Right to Buy)   (10)   (10) Common Stock 541 0.1 D  
Explanation of Responses:
1. 25% of the option vested on April 23, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. 25% of the option vested on September 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
3. Option vests in forty-eight (48) equal monthly installments, with the first installment vesting on April 7, 2024, subject to the Reporting Person's continued service on each such vesting date.
4. Option fully vested on September 30, 2025 following satisfaction by the Reporting Person of performance-based conditions.
5. Option vests in forty-eight (48) equal monthly installments, with the first installment vesting on October 10, 2025, subject to the Reporting Person's continued service on each such vesting date.
6. The Series A Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series A Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration.
7. The Series B Preferred Stock is convertible into Common Stock on a 1-for-9.2837 basis at any time at the option of the holder. The Series B Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration.
8. The Series C Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series C Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration.
9. The Series D Preferred Stock is convertible into Common Stock on a 1-for-9.7170 basis at any time at the option of the holder. The Series D Preferred Stock will convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration.
10. The warrants to purchase shares of Common Stock were immediately exercisable by their terms beginning on June 16, 2025. The Common Stock warrants will be exercised immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 on a net exercise basis.
Remarks:
Interim Chief Medical Officer and Executive Vice President, Translational Medicine
Exhibit 24 - Power of Attorney
/s/ Jolie M. Siegel, Attorney-in-Fact 05/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-24